Emma Andrus, Assistant Editor

Patients with atopic dermatitis were asked to rate the importance of several factors that may influence their decision to participate in a clinical trial.

Leading clinicians discuss sun protection best practices based on weather, climate, and travel needs.

Leading clinicians discuss sun protection and special issues in photosensitivity.

Leading clinicians debunk 5 of the most common sunscreen myths.

Leading clinicians discuss sun protection best practices and recommendations for the upcoming summer months.

Elaine Kung, MD, FAAD, discusses advancements in energy-based devices and the ways physicians in the dermatology space can advance their standard of care for patients with skin of color.

Researchers investigated the effects of combination mesoderm therapy and compound glycyrrhizin injections in patients with rosacea.

In a large cohort of transgender patients, gender-affirming hormone therapy did not have an effect on the incidence of skin cancers.

When compared to a vehicle treatment, patients with rosacea being treated with oxymetazoline had a more significant reduction facial erythema.

Several dermatologic conditions are known to be associated with anxiety disorders or mental health concerns.

Researchers said doxycycline, however, was more efficacious in reducing inflammatory lesions.

The pigment disorder is associated with several autoimmune and systemic comorbidities.

Researchers compared counts between patients with vitiligo and a control group of patients.

Researchers have identified what may be the first report of vitiligo induced de novo by dupilumab therapy.

Adam Friedman, MD, FAAD, discusses his RAD 2023 session, "Using Teledermatology to Reduce Disparities in Atopic Dermatitis."

A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.

Alexis discusses his Revolutionizing Atopic Dermatitis session, “Disparities in the Care of Atopic Dermatitis in the United States.”

The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.

The drug was both safe and effective in patients ages 6 months to 5 years.

Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.

Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.

In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.

In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.

In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.

Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.

Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.

Andrew Blauvelt, MD, MBA, discusses his RAD 2023 session, "Biologics for atopic dermatitis."

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

Among numerous sessions to be held this weekend at the Revolutionizing Atopic Dermatitis Conference in Washington, DC, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Revolutionizing Atopic Dermatitis Conference Chair Jonathan Silverberg, MD, PhD, MPH, previews this weekend's conference in Washington, DC.